Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656617 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00656617: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00656617 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 106 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656617, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS. Once the highest safe dose is found, researchers will then try to learn if this combination treatment can help to control AML and high-risk MDS in newly diagnosed patients. The safety of this treatment combination will also be studied.
Interventions
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2008-04 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656617
The ClinicalTrials.gov registry entry for NCT00656617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytarabine is the first listed.
NCT00656617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656617 about?
NCT00656617 is a clinical study titled "Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)". The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS. Once the highest safe dose is found, researchers will then try to learn if this combination treatment can he...
What is the current status of trial NCT00656617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2008-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00656617?
The interventions under investigation include: Cytarabine (DRUG), Idarubicin (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00656617?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.